Comprehensive care for patients with dry and atopy-prone skin: Arterium expands its portfolio of dermatological products with the new KERASKIN cosmetic line

Comprehensive care for patients with dry and atopy-prone skin: Arterium expands its portfolio of dermatological products with the new KERASKIN cosmetic line

Arterium, one of the market leaders in the dermatology segment*, has taken care of patients with chronic skin diseases for many years. Our portfolio includes products for the treatment of acute dermatoses and atopy. However, even after the completion of treatment, during the remission period, the skin of such patients requires constant care to avoid relapses. For this purpose, Arterium has developed KERASKIN, a new line of specialized cosmetic products, which provide daily care for dry, sensitive and atopy-prone skin.

 

The KERASKIN line consists of three dosage forms: cream in two presentations, milk and cleansing gel.

 

KERASKIN hypoallergenic cosmetic products contain a complex of active ingredients that promote intensive skin hydration for 48 hours, gently exfoliate dead skin cells, promote rapid skin regeneration, and eliminate the feeling of tightness and discomfort caused by dryness. After use, the skin becomes velvety to the touch, soft and elastic.

 

CREATED BY PHARMACISTS. TESTED BY DERMATOLOGISTS.

The KERASKIN product line has been tested at J.S. Hamilton, a leading Eastern European laboratory, under dermatological and pediatric control. The testing confirmed that KERASKIN can be used by both adults and children from the first days of their life.

The KERASKIN line for daily skin care is already available in pharmacies and online platforms.

 

* source: Procima Research study for months 1-11 of 2024, hospital+retail, in monetary terms

Дякуємо за звернення!

Ваша форма успішно відправлена. Якщо у вас виникли додаткові питання, будь ласка, заповніть форму на сайті або зателефонуйте нам

Pharmacovigilance

If you have any information about an adverse reaction and/or lack of efficacy of an Arterium Corporation drug, please fill out the form: